Dr. Marcom on Liquid Biopsies in Breast Cancer

Paul Kelly Marcom, MD
Published: Thursday, Oct 10, 2019



Paul Kelly Marcom, MD, a professor of medicine at Duke University School of Medicine and member of Duke Cancer Institute, discusses the use of liquid biopsies in breast cancer treatment.

Marcom does not feel as comfortable using liquid biopsies as he does tissue biopsies, even with assay metrics such as allele frequency. Despite Marcom’s discomfort with liquid biopsies, the SOLAR-1 trial highlighted a signal via cell-free DNA.

The degree of understanding and trust in liquid biopsy technology, according to Marcom, is 5 years behind next-generation sequencing from solid tumors. Currently, physicians can get a positive predictor out of finding a mutation using a liquid biopsy – if it is found. Physicians must be careful about excluding mutations, but the community is starting to gain confidence in the utility of these assays, Marcom concludes.
SELECTED
LANGUAGE


Paul Kelly Marcom, MD, a professor of medicine at Duke University School of Medicine and member of Duke Cancer Institute, discusses the use of liquid biopsies in breast cancer treatment.

Marcom does not feel as comfortable using liquid biopsies as he does tissue biopsies, even with assay metrics such as allele frequency. Despite Marcom’s discomfort with liquid biopsies, the SOLAR-1 trial highlighted a signal via cell-free DNA.

The degree of understanding and trust in liquid biopsy technology, according to Marcom, is 5 years behind next-generation sequencing from solid tumors. Currently, physicians can get a positive predictor out of finding a mutation using a liquid biopsy – if it is found. Physicians must be careful about excluding mutations, but the community is starting to gain confidence in the utility of these assays, Marcom concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication
x